Korean Gliptins Loom Amid Signs Of Shifts In India
Executive Summary
A clutch of new dipeptidyl peptidase-4 (DPP-4) inhibitors including LG Life Sciences Ltd's gemigliptin and Dong-A ST Co. Ltd 's evogliptin have either just hit the Indian market or are on the horizon amid what some industry watchers say are early signs of a shake-up in volumes in the highly competitive domestic gliptins market.
You may also be interested in...
Permanent Bar Against Glenmark's Sitagliptin Copies
The Delhi High Court has permanently enjoined Glenmark Pharmaceuticals Ltd from making and selling its generic version of Merck & Co's diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride). The Indian firm has been found to have infringed the sitagliptin patent.
India's mega-gliptins battle: shifting sands?
Brace yourself for more action in India's highly competitive dipeptidyl peptidase-4 (DPP-4) inhibitor market. Be it the vildagliptin versus sitagliptin tug-of-war or teneligliptin's price war cry or then second brand successes, there appears to be more in store in the space.
Glenmark 'pioneers' Mitsubishi's teneligliptin in India
Brace yourselves for a potential upsurge in action – both in price and probably elsewhere - in the dipeptidyl peptidase-4 (DPP-4) inhibitor segment in India.